Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, octobre 24
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
DiaMedica Therapeutics Inc
DMAC
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$8.72
0.09
1.04%
Dern. MÀJ: Oct 22, 9:30 AM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
DiaMedica Therapeutics Financials
DiaMedica Therapeutics (DMAC) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
DiaMedica Therapeutics Q2 EPS $(0.19) Beats $(0.20) Estimate
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5.56 percent decrease over losses of $(0.18) per share
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
DiaMedica Therapeutics Q1 EPS $(0.19), Inline
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 5.56 percent decrease over losses of $(0.18) per share from the same period last
Benzinga Newsdesk
PRO
DiaMedica Therapeutics Q4 EPS $(0.17) Beats $(0.18) Estimate
Benzinga Newsdesk
Earnings Scheduled For March 30, 2026
Benzinga Insights
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.
Avi Kapoor
